Asceneuron will attend the upcoming BIO International Convention next week, June 5-8 in Boston, MA! Our team is excited to connect with pharmaceutical executives to explore partnering and strategic opportunities in Alzheimer’s disease.

Our flagship clinical program, the OGA enzyme inhibitor ASN51, is a small molecule with confirmed long-lasting CNS target engagement in the human brain. The program is approaching Phase 2 at an accelerated pace. By targeting the toxic misfolding of proteins in the brain, ASN51 aims to effectively block tau pathology, thereby halting the progression of Alzheimer’s disease.

We are looking forward to meeting with you at BIO!

Our Head of Preclinical Development Bruno Permanne will present O-GLCNACASE INHIBITORS ASN90 AND ASN51 ARE MULTIMODAL DRUG CANDIDATE FOR AD AND PD at the Symposium “Exploring new targets in AD, PD and LBD” taking place on Saturday, April 1st, Hall F4-F5. The lecture is scheduled for 12:10 pm CET.

BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.

This year the BIO-Europe Spring program will showcase three thematic pillars, featuring a mix of keynotes from Life science Execs, fireside chats, panel discussions and presentations.

Asceneuron’s CEO and founder Dirk Beher shared his views on the remaining challenges of tackling diseases like PSP and Alzheimer’s disease in an article by George Underwood in Pharmaphorum.

The Latsis symposium will gather leading scientists from different disciplines to discuss the latest findings, share the latest advances, and brainstorm collectively about how to leverage and integrate the latest advances in imaging and image analyses to address current knowledge and technological gaps and advance translational research in neurodegenerative diseases.

Our CEO, Dirk Beher, will participate in the panel “Treating Neurodegenerative Diseases: How far we have come and how far we still have to go?” at the Rolex Center, EPFL, on August 31st at 6:50 pm. He will talk about the Alzheimer’s disease.

This conference will draw experts in O-GlcNAc biology from around the world to discuss how O-GlcNAc and O-GlcNAc cycling enzymes modulate protein function in basic biological processes as well as in disease states, including diabetes, cancer, cardiovascular disease and neurological diseases.

Conference program

Our Head of Translational Medicine Dr Ryan Schubert will present “Human pharmacology highlights the potential of the ASN51 as an ideal once-a-day oral drug for the treatment of neurodegenerative diseases” at the session “O-GlcNAcylation and neuronal functions and disease” scheduled from 9:00 am to 12:00 am on Sunday, July 10th.

Poster session

Our Head of Preclinical Development Dr Bruno Permanne will present a poster “ASN51, an Orally Bioavailable Small-molecule O-GlcNAcase Inhibitor, has both immediate and Disease-Modifying Benefits in Preclinical Models of Parkinson’s Disease”.Asceneuron is proud to support this event as a sponsor in its commitment to advancing and promoting research on O-GlcNAc biology to find novel treatments for numerous human diseases.

Further information about the event can be found here.